Gene
ERCC2
ERCC2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (10), Actionable biomarkers (1), Trial mentions (6), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ERCC2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
ERCC2 has 6 trial mentions across 6 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 1 of 11,460 | 0.01% |
| 2022 | 0 of 8,285 | 0.00% | 6 of 13,598 | 0.04% |
| 2021 | 0 of 8,692 | 0.00% | 11 of 15,045 | 0.07% |
| 2020 | 0 of 7,640 | 0.00% | 6 of 14,459 | 0.04% |
| 2019 | 0 of 7,300 | 0.00% | 9 of 12,159 | 0.07% |
| 2018 | 1 of 6,927 | 0.01% | 9 of 11,854 | 0.08% |
| 2017 | 1 of 6,558 | 0.02% | 8 of 11,595 | 0.07% |
Showing 10 of 37 years.
Assay-provider ledger (10)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Belay Diagnostics | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 01, 2025 |
| Acornmed Biotechnology | Diagnostic provider | Clinical validation | 1 | October 01, 2024 |
| Genetron Health | Diagnostic provider | Clinical validation | 1 | September 27, 2024 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 2 | September 27, 2024 |
| ZYMO Research (Orange, CA) | Reagent supplier | Clinical validation | 1 | September 27, 2024 |
Showing 5 of 10 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ERCC2 oncogenic mutation | CISPLATIN | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (6)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00728000 | Trial eligibility (AACT) |
| NCT03061188 | Trial eligibility (AACT) |
| NCT03448718 | Trial eligibility (AACT) |
| NCT06439225 | Trial eligibility (AACT) |
| NCT00515216 | Trial outcomes (AACT) |
Showing 5 of 6 trial mentions.
Target-disease associations (589)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ALDH18A1-related de Barsy syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Abnormality of the gastrointestinal tract | phenotype | GWAS credible sets |
| Acanthamoeba keratitis | disorder of visual system | Mouse knockout (IMPC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 589 associations.
Vendor sourcing (48)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | It is not observed in the gnomAD v2.1.1 dataset (PM2). Missense changes are a common disease-causing mechanism (PP2). In silico tool predictions suggest no d... | View ClinVar record SCV002011915.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | ERCC2 | View trial NCT03061188 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein ... | View ClinVar record SCV002605615.2 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | #8) may have an ECOG Performance Status of ≤ 2. * Histological or cytological evidence/confirmation of urothelial cancer. * Metastatic and/or unresectable (c... | View trial NCT03448718 |
Showing 5 of 48 sourcing records.
Trial-cited literature (108)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 55 |
| Daily yogurt consumption does not affect bone turnover markers in men and postmenopausal women of Caribbean Latino descent: a randomized controlled trial. | BMC nutrition | 2024 | 9 |
| Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. | Nature medicine | 2023 | 131 |
| A pan-cancer compendium of chromosomal instability. | Nature | 2022 | 234 |
| DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. | Frontiers in oncology | 2022 | 12 |
Showing 5 of 108 papers.
Protein variant mentions (45)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A182V | 1 | 2015 | PMID 25741868 |
| p.A717G | 2 | 2015 to 2018 | PMID 29607586, PMID 25741868 |
| p.D312E | 2 | 2001 to 2009 | PMID 20066159, PMID 11751380 |
| p.D423N | 1 | 2015 | PMID 25741868 |
| p.D609G | 1 | 2014 | PMID 25096233 |
Showing 5 of 45 variants.
Human sample screening reference (5)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.E86Q | TCGA-BLCA | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Squamous Cell Neoplasms; Transitional Cell Papillomas and Carcinomas; Bladder | 1 | 412 | 0.24% | 0.04% to 1.36% |
| p.Q758E | TCGA-BLCA | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Squamous Cell Neoplasms; Transitional Cell Papillomas and Carcinomas; Bladder | 1 | 412 | 0.24% | 0.04% to 1.36% |
| p.S44L | TCGA-BLCA | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Squamous Cell Neoplasms; Transitional Cell Papillomas and Carcinomas; Bladder | 3 | 412 | 0.73% | 0.25% to 2.12% |
| p.T484M | CPTAC-3 | Not Applicable; Transitional Cell Papillomas and Carcinomas; Ductal and Lobular Neoplasms; Adenomas and Adenocarcinomas; Gliomas; Epithelial Neoplasms, NOS; Complex Epithelial Neoplasms; Complex Mixed and Stromal Neoplasms; Lipomatous Neoplasms; Squamous Cell Neoplasms; Myeloid Leukemias; Nevi and Melanomas; Stomach; Other and ill-defined sites in lip, oral cavity and pharynx; Unknown; Colon; Other and unspecified urinary organs; Floor of mouth; Other and unspecified parts of mouth; Gum; Bronchus and lung; Oropharynx; Other and unspecified parts of tongue; Base of tongue; Breast; Other and ill-defined sites; Larynx; Lip; Uterus, NOS; Hematopoietic and reticuloendothelial systems; Kidney; Brain; Skin; Pancreas; Tonsil | 1 | 1,815 | 0.06% | 0.01% to 0.31% |
| p.T484M | TCGA-BLCA | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Squamous Cell Neoplasms; Transitional Cell Papillomas and Carcinomas; Bladder | 1 | 412 | 0.24% | 0.04% to 1.36% |
Literature-extracted relations (26)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| EVEROLIMUS | Chemical | associate |
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. | 2021 |
| CISPLATIN | Chemical | negative_correlate |
The DNA damage response network in the treatment of head and neck squamous cell carcinoma. | 2021 |
| CISPLATIN | Chemical | associate |
<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. | 2019 |
| CISPLATIN | Chemical | associate |
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. | 2014 |
| Irinotecan | Chemical | associate |
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. | 2009 |
Showing 5 of 26 relation assertions.
Organizations publishing (130)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 9 | 2014 to 2021 |
| Dana-Farber Cancer Institute | Other | 8 | 2014 to 2021 |
| Government of the United States of America | Government | 8 | 2010 to 2022 |
| Temple University Health System | Academic | 7 | 2015 to 2025 |
| Harvard Medical School | Academic | 6 | 2014 to 2023 |
Showing 5 of 130 organizations.
Where ERCC2 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- urinary system disease
534 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.